We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

21 hedge funds and large institutions have $2.36M invested in VistaGen Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

0.24% less ownership

Funds ownership: 0.49% → 0.25% (-0.24%)

16% less funds holding

Funds holding: 25 → 21 (-4)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

70% less capital invested

Capital invested by funds: $7.99M → $2.36M (-$5.62M)

Holders
21
Holders Change
-4
Holders Change %
-16%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
3
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HighTower Advisors
HighTower Advisors
Illinois
+$89.6K
2
Wells Fargo
Wells Fargo
California
+$38.3K
3
LPL Financial
LPL Financial
California
+$33.2K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$31.6K
5
UBS Group
UBS Group
Switzerland
+$13.7K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.66M
2
SFM
Sphera Funds Management
Israel
-$1.19M
3
ECM
Endurant Capital Management
California
-$462K
4
WVP
Worth Venture Partners
New Jersey
-$203K
5
AAP
Ardsley Advisory Partners
Connecticut
-$32K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$868K +$31.6K +1,191 +3%
SFM
2
Sphera Funds Management
Israel
$489K -$1.19M -44,948 -67%
PVI
3
Pura Vida Investments
New York
$308K – – –
LTFS
4
Ladenburg Thalmann Financial Services
Florida
$126K -$159 -6 -0.1%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$122K +$12.7K +479 +9%
HighTower Advisors
6
HighTower Advisors
Illinois
$96K +$89.6K +3,377 +326%
DADC
7
D.A. Davidson & Co
Montana
$60K -$28.3K -1,067 -28%
Northern Trust
8
Northern Trust
Illinois
$51K – – –
Carson Wealth (CWM LLC)
9
Carson Wealth (CWM LLC)
Nebraska
$43K – – –
Parallax Volatility Advisers
10
Parallax Volatility Advisers
California
$32K – – –
Wells Fargo
11
Wells Fargo
California
$31K +$38.3K +1,443 New
LPL Financial
12
LPL Financial
California
$27K +$33.2K +1,250 New
RC
13
RBF Capital
California
$18K – – –
FAIM
14
Financial Advocates Investment Management
Washington
$17K – – –
GBA
15
Garrison Bradford & Associates
New York
$15K – – –
HFM
16
Hartford Financial Management
Connecticut
$12K +$1.75K +66 +14%
CWA
17
Clarus Wealth Advisors
Arizona
$11K – – –
FSA
18
Fort Sheridan Advisors
Illinois
$11K – – –
UBS Group
19
UBS Group
Switzerland
$11K +$13.7K +517 New
Morgan Stanley
20
Morgan Stanley
New York
$9K +$80 +3 +0.7%
PNC Financial Services Group
21
PNC Financial Services Group
Pennsylvania
$5K – – –
Point72 Asset Management
22
Point72 Asset Management
Connecticut
– -$1.66M -43,333 Closed
ECM
23
Endurant Capital Management
California
– -$462K -12,031 Closed
WVP
24
Worth Venture Partners
New Jersey
– -$203K -5,278 Closed
AAP
25
Ardsley Advisory Partners
Connecticut
– -$32K -833 Closed
1
2

VTGN Hedge Fund Activity: Q2 2019 in Review

21 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2019, worth a combined $2.36M — down 70% from $7.99M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of VTGN and 3 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was HighTower Advisors, adding an estimated $89.6K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.66M sold.

  • 21 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2019, down from 25 in Q1 2019.
  • Funds reported $2.36M of VistaGen Therapeutics stock for Q2 2019, down 70% quarter-over-quarter.
  • 3 funds opened new VistaGen Therapeutics positions in Q2 2019 and 7 closed out, a net change of -4 holders.
  • The largest VistaGen Therapeutics buyer in Q2 2019 was HighTower Advisors, an estimated $89.6K added.
  • The largest VistaGen Therapeutics seller in Q2 2019 was Point72 Asset Management, an estimated $1.66M sold.

Based on aggregated 13F filings for Q2 2019.